HER2 Antibodies Epitope Segmentation Dimerization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HER2-targeted therapies, such as trastuzumab and pertuzumab, have limitations in efficacy and specificity, particularly in internalization efficiency and broad applicability across HER2 expression levels, necessitating the development of more effective and specific monoclonal antibodies for treating HER2-related cancers.
Innovation Solution
Development of novel fully human monoclonal HER2 antibodies that bind to distinct epitopes, exhibit enhanced internalization, and demonstrate improved ADCC-mediated killing of HER2-expressing cells, with the ability to target both high and low HER2 expression levels, and are designed for use as ADCs or bispecific formats to enhance therapeutic outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If trastuzumab is used to block HER2 homodimerization, then ligand-independent HER2 homodimerization is inhibited, but efficacy is limited to 20-50% of HER2 overexpressing breast tumor patients and relapse occurs after a few months
Solution Approach 1:
The patent divides the HER2 extracellular domain into multiple epitope regions (domain I-IV) and develops antibodies targeting each segment independently. This segmentation allows the therapy to address different HER2 expression levels and dimerization states, thereby improving both durability of response and adaptability across different patient subgroups.
Solution Approach 2:
The patent creates a multi-functional antibody therapy that can simultaneously block homodimerization, inhibit heterodimerization, prevent ectodomain shedding, and mediate ADCC. This multi-functionality enables the therapy to be effective across diverse patient populations with varying HER2 expression levels, addressing both durability and versatility requirements.
2Reliability
If pertuzumab is used to inhibit heterodimerization, then ligand-induced heterodimerization is blocked, but internalization efficiency is reduced compared to trastuzumab
Solution Approach 1:
The patent combines the dimerization blockade mechanism of pertuzumab (targeting domain II) with the internalization enhancement mechanism of trastuzumab (targeting domain IV). By developing bispecific antibodies or combining both mechanisms in a single therapy, the patent achieves both reliable dimerization inhibition and high internalization efficiency.
Solution Approach 2:
The patent employs composite antibody structures, including bispecific antibodies that integrate different epitope-specific binding domains. This composite approach allows the therapy to simultaneously achieve dimerization blockade and enhanced internalization, resolving the contradiction between reliability of dimerization inhibition and productivity of internalization.
3Object-affected harmful factors
If trastuzumab is used to prevent ectodomain shedding, then constitutively active truncated protein formation is prevented, but the mechanism requires high HER2 overexpression levels
Solution Approach 1:
The patent applies different antibody mechanisms to different local regions of the HER2 protein. Antibodies targeting domain IV (like trastuzumab) are used to prevent ectodomain shedding in high-expression contexts, while antibodies targeting other domains are employed in low-expression contexts. This localized approach maintains effectiveness across varying HER2 expression levels while preventing harmful truncated protein formation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These antibodies show increased efficacy in killing HER2-expressing tumor cells, improved internalization, and enhanced ADCC, providing effective treatment options for both high and low HER2-expressing cancers, potentially offering better therapeutic outcomes compared to existing therapies.
Implementation Method 1
monoclonal antibodies directed to human epidermal growth factor receptor 2 (HER2)
Implementation Method 2
Trastuzumab mediates antibody-dependent cellular cytotoxicity (ADCC)
Implementation Method 3
Trastuzumab mediates antibody-dependent cellular cytotoxicity (ADCC) and prevents ectodomain shedding
Data Source
Figure 1A~1B
Figure 1C~1D
Figure 1E~1F
AI summary
Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.